P33 RKER-065 ameliorated muscle and bone loss in a progressive murine model of Duchenne muscular dystrophy

Patients with Duchenne muscular dystrophy (DMD) have reduced muscle mass and function. They also exhibit low bone strength leading to a higher risk of skeletal fractures. Minimal treatment options include the current standard of care long-term corticosteroids, which further reduce muscle and bone mass. The TGF- β superfamily of ligands, including myostatin and activins, signal through activin type II receptors (ActRII) and negatively regulate muscle and bone mass and function. KER-065 is an investigational, novel modified ActRII-Fc ligand trap designed to target these catabolic ligands.

Source: Neuromuscular Disorders - October 1, 2023 Category: Neurology Authors: R. Nathan, M. Cahill, R. Todorova, S. Macaluso, C. Tseng, F. Fisher, L. Lerner, J. Seehra, J. Lachey Source Type: research